Novelli, SilvanaBento, LeyreGarcia, IrenePrieto, LauraLopez, LuciaGutierrez, GonzaloHernani, RafaelPerez, AriadnaEsquirol, AlbertSolano, CarlosBastos, MarianaDorado, NievesRodriguez, NancyRodriguez, GuillermoPiñana, Jose LMontoro, JuanHerrera, PilarLuna, AlejandroParody, RocioMartín, CarmenGarcia, EstefaniaLopez, OrianaHeras, InmaculadaZanabili, JoudMoraleda, Jose MYañez, LucreciaGutierrez, AntonioZudaire, TeresaCordoba, RaulVarela, RosarioFerra, ChristelleMartinez, JoaquinMartinez, CarmenGonzalez-Barca, EvaMartino, RodrigoCaballero, Dolores2023-02-092023-02-092021-03-15Novelli S, Bento L, Garcia I, Prieto L, López L, Gutierrez G, et al. Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers. Transplant Cell Ther. 2021 Jun;27(6):493.e1-493.e8.http://hdl.handle.net/10668/17585Despite advances in understanding the biology of mature T and natural killer (NK)/T cell neoplasia, current therapies, even the most innovative ones, are still far from ensuring its cure. The only treatment to date that has been shown to control aggressive T cell neoplasms in the long term is allogeneic stem cell transplantation (alloSCT). We aim to report the results of alloSCT for advanced mature T and NK/T neoplasias performed in centers from our national GELTAMO/GETH (Grupo Español de Linfoma y Trasplante de Médula Ósea/Grupo Español de Trasplante Hematopoyético y Terapia Celular) over the past 25 years. As a secondary objective, we analyzed the results of alloSCT from haploidentical donors. We performed a retrospective analysis of all patients who received an alloSCT in Spanish centers (n = 201) from September 1995 to August 2018. The 2-year overall survival (OS) and disease-free survival (DFS) were 65.5% and 58.2%, respectively. The univariate for OS and DFS showed statistically different hazard ratios for conditioning intensity, response pre-alloSCT, comorbidity index, donor/receptor cytomegalovirus status and Eastern Cooperative Oncology Group (ECOG) pre-alloSCT, but only a better ECOG pre-alloSCT remained significant in the multivariate analysis. There was an increased incidence of relapse in those patients who did not develop chronic graft-versus-host disease (GVHD) and an increased risk of death in those developing moderate to severe acute GVHD. The 1-year nonrelapse mortality was 21.9% and was mainly due to GVHD (30%) and bacterial infections (17%). When comparing unrelated donors with haploidentical donors, we found similar results in terms of OS and DFS. There was, however, a reduction of acute GVHD in the haploidentical group (P = .04) and trend to a reduction of chronic GVHD. In conclusion, alloSCT is the only curative option for most aggressive T cell neoplasias. Haploidentical donors offer similar results to related donors in terms of survival with a reduction of acute GVHD.enAtribución-NoComercial-SinDerivadas 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Allogeneic stem cell transplantationHaploidenticalT cell lymphomaHematopoietic Stem Cell TransplantationHumansKiller Cells, NaturalNeoplasm Recurrence, LocalRegistriesRetrospective StudiesTransplantation Conditioningresearch article33857447open accessDonantes de tejidosNeoplasiasLinfocitos TPacientesSíndrome de bronquiolitis obliteranteInfecciones bacterianasCitomegalovirusRecurrenciaSupervivencia sin enfermedadIncidencia10.1016/j.jtct.2021.03.0142666-6367https://doi.org/10.1016/j.jtct.2021.03.014